Toggle navigation
About Us
Portfolio
News
Contact Us
Lightchain Capital
Recent News
July 10, 2023
Q&A with Rory Johnson, PhD
READ MORE
July 05, 2023
C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDACâ„¢ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer
READ MORE
June 21, 2023
Small box. Big ambitions
READ MORE
June 21, 2023
Q&A with Susan Carpenter, PhD
READ MORE
June 20, 2023
C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer
READ MORE
June 06, 2023
Q&A with John Mattick, PhD
READ MORE
May 31, 2023
AI Proteins Announces the Formation of a Scientific Advisory Board Made up of Experts in Biotech and FDA Drug Approval
READ MORE
May 30, 2023
C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDACâ„¢ Degrader of EGFR L858R for NSCLC
READ MORE
May 22, 2023
St. Louis high-potential tech startup emerges from stealth mode
READ MORE
May 18, 2023
AI Proteins Expands Leadership Team with Two Key Hires
READ MORE
1
2
3
4
5
6
...
21
Contact Us
Lightchain Capital, LLC
PO Box 31729
St. Louis, MO 63131
Submit
4837,4748,4815,4823,4811,4819,4822,4748,4772,4748,4789,4811,4830,4819,4815,4760,4792,4760,4791,4825,4828,4817,4811,4824,4778,4825,4831,4830,4822,4825,4825,4821,4760,4813,4825,4823,4748,4758,4748,4829,4831,4812,4820,4815,4813,4830,4748,4772,4748,4781,4825,4824,4830,4811,4813,4830,4746,4784,4825,4828,4823,4748,4839
©2021 LIGHTCHAIN CAPITAL, LLC All Rights Reserved |
Privacy Policy
Website by
Tidal Media Group